Concurrent Session 2C: Personalized Nutrition: The Impact of Diet and the Microbiome on Disease Risk

Wednesday, September 12
1:30 PM - 3:00 PM

Learning Objectives:

Moderator :
Purna Kashyap, MBBS

Assistant Professor of Medicine, College of Medicine and Science
Center for Individualized Medicine
Mayo Clinic
Rochester, Minnesota

Purna Kashyap, PhD has a research program which aims to better understand the pathogenesis of functional gastrointestinal disorders and develop newer treatment options for patients. The current understanding of the disease process remains poor, and as a result treatment options are very limited and fail to address the underlying causes. They also hope to extend this knowledge to address other diseases associated with changes in human gut bacteria such as C. difficile colitis and obesity. The human gastrointestinal (GI) tract harbors 100 trillion microbes that live in harmony with their human host and perform processes vital for health. Changes in the normal gut microbiota have been associated with a number of disease states with changes in gastrointestinal (GI) motility, such as irritable bowel syndrome and Clostridium difficile colitis. The Kashyap laboratory primarily focuses on the influence of gut bacteria on gastrointestinal physiology by modulating host pathways such as the serotonergic system. They use targeted and non-targeted metabolomics, transcriptomics, and genomics in combination with gnotobiotic mouse modelsto help identify novel bacterial taxa and microbial metabolites which affect the key players involved in gastrointestinal motility, secretion and sensation. In order to better understand the role of human derived gut microbes they use the humanized mouse model where colonize germ free mice with human derived bacteria to allow us to more effectively translate our findings and develop targeted therapies for humans. They have recently described the role of gut microbiota derived short chain fatty acids in increasing serotonin biosynthesis and release using these methods. The long-term goal of our research is to develop new biomarkers and microbiota-targeted therapies for treatment of functional gastrointestinal disorders, including irritable bowel syndrome. Furthermore the Kashyap lab is interested in engineering commensal gut bacteria to produce a metabolite of interest, which will help overcome deficiencies in the current approach of probiotics.

Presentation(s):

Send Email for Purna Kashyap

Concurrent Speaker - Int:
Jens Walter, PhD

Presentation(s):

Send Email for Jens Walter

Concurrent Speaker :
Christoph A. Thaiss, PhD

Assistant Professor
University of Pennsylvania

Presentation(s):

Send Email for Christoph Thaiss

Concurrent Speaker :
Tali Raveh-Sadka, PhD

Director of Research
DayTwo

Tali Raveh-Sadka, PhD is the Director of Research at DayTwo. Tali holds a PhD in computational biology. She has a background in Machine learning, Computational Biology and Metagenomics. Tali completed her doctoral thesis on transcriptional regulation in the lab of Prof. Eran Segal at the Weizmann Institute and did her postdoctoral research on gut microbiomes of preterm infants in the lab of Prof. Jill Banfield at UC Berkeley.

Presentation(s):

Send Email for Tali Raveh-Sadka


Assets

Concurrent Session 2C: Personalized Nutrition: The Impact of Diet and the Microbiome on Disease Risk



Attendees who have favorited this

Please enter your access key

The asset you are trying to access is locked. Please enter your access key to unlock.

Send Email for Concurrent Session 2C: Personalized Nutrition: The Impact of Diet and the Microbiome on Disease Risk